Gene Expression Profiles Discriminate between Pathological Complete Response and Resistance to Neoadjuvant FEC100 in Breast Cancer

In breast cancer treatment, FEC100 (fluorouracil, epirubicin and cyclophosphamide) chemotherapy delivered in a neoadjuvant setting is still applied empirically to all patients. The aim of this study was to establish a multigene classifier of sensitivity to neoadjuvant FEC100. cDNA nylon microarrays,...

Full description

Saved in:
Bibliographic Details
Published inCancer genomics & proteomics Vol. 3; no. 2; p. 89
Main Authors Millour, Marie, Charbonnel, Catherine, Magrangeas, Florence, Minvielle, Stéphane, Campion, Loïc, Gouraud, Wilfried, Campone, Mario, Déporte-Féty, Régine, Bignon, Yves-Jean, Penault-Llorca, Frédérique, Jézéquel, Pascal
Format Journal Article
LanguageEnglish
Published Greece 01.03.2006
Subjects
Neoadjuvant fluorouracil
epirubicin and cyclophosphamide chemotherapy
gene expression profiles
breast cancer
drug resistance
Online AccessGet more information

Cover

More Information
Summary:In breast cancer treatment, FEC100 (fluorouracil, epirubicin and cyclophosphamide) chemotherapy delivered in a neoadjuvant setting is still applied empirically to all patients. The aim of this study was to establish a multigene classifier of sensitivity to neoadjuvant FEC100. cDNA nylon microarrays, containing 15,000 genes, were used to analyze the gene expression profiles of tumour biopsies collected before chemotherapy: 8 were typed as pathological complete responders and 8 as non-responders according to their histological and clinical responses. A classifier was generated by means of Linear Discriminant Analysis and was evaluated by leave-one-out cross-validation. The difference of expression of the NDUFB5 gene (NADH dehydrogenase 1 beta subcomplex, 5), the best discriminating gene, was verified using RT-PCR. This preliminary work requires further investigations, especially in terms of larger cohorts, before the results can be transferred to clinical practice.
ISSN:1790-6245